Clinical trials: Squamous-Cell Lung Cancer
Non-squamous Non-small-cell Lung Cancer, Brain Metastases
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
The primary hypothesis is that camrelizumab in combination with pemetrexed/ carboplatin will present a better efficacy for treatment of first line metastatic non-squamous non-small cell lung cancer and minimize the risk of…
- Trial name
- CAP-BRAIN (NCT04211090)
- Testing
- Camrelizumab, Pemetrexed, Carboplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Non-squamous Non-small Cell Lung Cancer
Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel
The purpose of this clinical study is to evaluate the tolerability and toxicity of different dose of Anlotinib puls Pemetrexed/Docetaxel in Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer …
- Trial name
- NCT03566576
- Testing
- Anlotinib, Pemetrexed, Docetaxel
- Volunteers
- 18 people
- Sponsor
- Fujian Cancer Hospital
Healthy Volunteers, Pancreatic Ductal Adenocarcinoma
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
This is a Phase 1a, open label, single dose, extended study of safety and biokinetics of RAD301 in healthy human volunteers and individuals with PDAC or Other Solid Tumors
- Conditions
- Healthy Volunteers, Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Esophageal Squamous Cell Carcinoma
- Trial name
- RAD301 (NCT05799274)
- Testing
- RAD301 ([68Ga]-RAD301)
- Where
- 2 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Radiopharm Theranostics, Ltd
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Non-Squamous Non-Small Cell Lung Cancer
An Observational Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
This prospective observational study will evaluate the efficacy and safety of Tarceva (erlotinib) in elderly patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen.
- Trial name
- NCT01535729
- Where
- Germany
- Volunteers
- 465 people
- Sponsor
- Hoffmann-La Roche
Lungcancer
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung
MEK162 has shown significant inhibition of tumor growth as a single agent in NSCLC xenograft models in mice and human cancer cells in vitro, which have KRAS and/or other mutations.
- Trial name
- MEK162 (NCT02185690)
- Testing
- Binimetinib, Pemetrexed, Carboplatin
- Where
- 4 sites in Canada
- Volunteers
- 13 people
- Sponsor
- University Health Network, Toronto
Lung Cancer
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00526890
- Testing
- selenomethionine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
NSCLC Stage II, NSCLC, Stage IIIA
Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC
Exploratory study evaluating the potential of immune signature profiling for predicting response in patients with resectable Stage II, IIIA and select IIIB (T3N2 only) non-squamous Non-Small Cell Lung Cancer (NSCLC) to…
- Conditions
- NSCLC Stage II, NSCLC, Stage IIIA, NSCLC Stage IIIB
- Trial name
- iReP (NCT04865250)
- Testing
- Atezolizumab 1200 mg abs day 1 q22 (iv)
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal
A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies
The purpose of this study is to learn about the safety and the effects of PF-08046037 alone or with sasanlimab for the treatment of certain advanced or metastatic malignancies.
- Conditions
- Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal, Malignant Melanoma, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
- Trial name
- NCT06974734
- Testing
- PF-08046037, sasanlimab
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 8 people
- Sponsor
- Pfizer
Non-small Cell Lung Cancer
dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.
To date, there are no methods to reliably select which patients with non-squamous non-small cell lung cancer (NSCLC) that benefit most from treatment with bevacizumab.
- Trial name
- BevMar (NCT02195336)
- Testing
- dMRT, Bevacizumab, paclitaxel and carboplatin
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karl Kölbeck
NSCLC, NSCLC Stage IV
Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer
This is a Phase I open label multi-center study to evaluate the safety, tolerability, pharmacokinetics and preliminary effectiveness of the investigational drug MYTX-011 in patients with locally advanced, recurrent or metastatic…
- Conditions
- NSCLC, NSCLC Stage IV, NSCLC Stage IIIB, Non-Small Cell Lung Cancer
- Trial name
- NCT05652868
- Testing
- MYTX-011
- Where
- 55 sites in United States, Australia and 5 more
- Volunteers
- 227 people
- Sponsor
- Mythic Therapeutics
Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity, Untreated With Systemic Therapy
Clinical Study on Nanocrystalline Megestrol Acetate for Appetite Improvement and Weight Gain in Pre-Cachexia and Cachexia Stages Key Terminology Analysis
The purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (NSCLC) and cachexia and…
- Trial name
- NCT06961188
- Testing
- Nano-crystalline Megestrol Acetate Oral Suspension, Standard Therapy
- Where
- China
- Volunteers
- 174 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced
Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
A study of ADI-PEG 20 (pegylated arginine deiminase), an arginine degrading enzyme in patients with histologically proven advanced malignant pleural mesothelioma (MPM), advanced peritoneal mesothelioma (in dose escalation cohort…
- Conditions
- Pleural Mesothelioma Malignant Advanced, Peritoneal Mesothelioma Malignant Advanced, Non-squamous Non-small Cell Lung Carcinoma, Uveal Melanoma
- Trial name
- TRAP (NCT02029690)
- Testing
- ADI-PEG 20
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 85 people
- Sponsor
- Polaris Group
Lung Cancer
Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma
The purpose of this study is studying induction nimotuzumab plus gemcitabine and carboplatin followed by surgery to see how well it works in treating patients with unresectable stage III squamous cell lung carcinoma.
- Trial name
- NCT02428764
- Testing
- Nimotuzumab, Gemcitabine, Carboplatin
- Where
- China
- Sponsor
- Sun Yat-sen University
Non-Small-Cell Lung Carcinoma
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study
This is a Japan Extension Study of Global Study MK-3475-189 (NCT02578680). This is an efficacy and safety study of pembrolizumab (MK-3475) combined with pemetrexed/platinum chemotherapy versus pemetrexed/platinum chemotherapy…
- Trial name
- NCT03950674
- Testing
- Pembrolizumab 200 mg, Cisplatin, Carboplatin
- Where
- 10 sites in Japan
- Volunteers
- 40 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer, Head and Neck Cancer
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
This is a phase 1, multi-center, dose escalation, open-label study to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of JAB-3068 in adult patients with advanced solid.
- Conditions
- Non-small Cell Lung Cancer, Head and Neck Cancer, Esophageal Cancer, Other Metastatic Solid Tumors
- Trial name
- NCT03518554
- Testing
- JAB-3068
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Lung Cancer, Lung Adenocarcinoma
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this…
- Conditions
- Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT06255197
- Where
- China
- Volunteers
- 60,000 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Squamous Cell Carcinoma
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
The treatment of squamous cell carcinoma of lung has not improved suffuciently. Nedaplatin is a second-generation platinum compound that is more active against squamous cell carcinoma of the lung with a response rate of 60%…
- Trial name
- NCT02088515
- Testing
- Nedaplatin, Cisplatin, Docetaxel
- Where
- 4 sites in China
- Volunteers
- 290 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens
This phase II trial studies how well nintedanib works in treating patients with advanced non-small cell lung cancer who have failed up to two previous chemotherapy regimens.
- Conditions
- Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage III Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
- Trial name
- NCT01948141
- Testing
- nintedanib
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.